GSK plc Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-03-24: Form 6-K; Period of report 2023-03-24; Description STATEMENT: ZANTAC (RANITIDINE) LITIGATION; Document a1681u.htm.
- 2023-03-21: Form 6-K; Period of report 2023-03-21; Description DIRECTOR/PDMR SHAREHOLDING; Document a7517t.htm.
- 2023-03-20: Form 6-K; Period of report 2023-03-20; Description DIRECTOR/PDMR SHAREHOLDING; Document a5451t.htm.
- 2023-03-14: Form 6-K; Period of report 2023-03-14; Description POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE; Document a8290s.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2023-03-24 | 6-K | 2023-03-24 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a1681u.htm |
| 2023-03-21 | 6-K | 2023-03-21 | DIRECTOR/PDMR SHAREHOLDING | a7517t.htm |
| 2023-03-20 | 6-K | 2023-03-20 | DIRECTOR/PDMR SHAREHOLDING | a5451t.htm |
| 2023-03-14 | 6-K | 2023-03-14 | POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE | a8290s.htm |
| 2023-03-14 | 6-K | 2023-03-14 | NUCALA NDA ACCEPTED FOR REVIEW IN CHINA | a8289s.htm |
| 2023-03-13 | 6-K | 2023-03-13 | DIRECTOR/PDMR SHAREHOLDING | a6434s.htm |
| 2023-03-10 | 6-K | 2023-03-10 | GSK ANNUAL REPORT 2022 ON FORM 20-F | a6394s.htm |
| 2023-03-10 | 6-K | 2023-03-10 | GSK PUBLISHES ANNUAL REPORT 2022 | a5980s.htm |
| 2023-03-02 | 6-K | 2023-03-02 | FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE | a5988r.htm |
| 2023-03-01 | 6-K | 2023-03-01 | TOTAL VOTING RIGHTS | a4097r.htm |
| 2023-02-27 | 6-K | 2023-02-27 | DIRECTOR/PDMR SHAREHOLDING | a1810r.htm |
| 2023-02-23 | 6-K | 2023-02-23 | DIRECTOR/PDMR SHAREHOLDING | a8602q.htm |
| 2023-02-23 | 6-K | 2023-02-23 | VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA | a8275q.htm |
| 2023-02-22 | 6-K | 2023-02-22 | DIRECTOR/PDMR SHAREHOLDING | a7521q1.htm |
| 2023-02-16 | 6-K | 2023-02-16 | NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL | a0852q.htm |
| 2023-02-15 | 6-K | 2023-02-15 | DIRECTOR/PDMR SHAREHOLDING | a0570q.htm |
| 2023-02-15 | 6-K | 2023-02-15 | DIRECTOR/PDMR SHAREHOLDING | a0543q.htm |
| 2023-02-14 | 6-K | 2023-02-14 | DIRECTOR/PDMR SHAREHOLDING | a7925p.htm |
| 2023-02-14 | 6-K | 2023-02-14 | DIRECTOR/PDMR SHAREHOLDING | a7929p.htm |
| 2023-02-14 | 6-K | 2023-02-14 | DIRECTOR/PDMR SHAREHOLDING | a7927p.htm |
| 2023-02-14 | 6-K | 2023-02-14 | DIRECTOR/PDMR SHAREHOLDING | a7907p.htm |
| 2023-02-10 | 6-K | 2023-02-10 | DIRECTOR/PDMR SHAREHOLDING | a6271p.htm |
| 2023-02-10 | 6-K | 2023-02-10 | JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL | a5649p.htm |
| 2023-02-10 | 6-K | 2023-02-10 | JEMPERLI FDA ODAC POSITIVE OUTCOME | a5216p.htm |
| 2023-02-02 | 6-K | 2023-02-02 | DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD | a6664o.htm |
| 2023-02-01 | 6-K | 2023-02-01 | DIRECTOR/PDMR SHAREHOLDING | a5679o.htm |
| 2023-02-01 | 6-K | 2023-02-01 | TOTAL VOTING RIGHTS | a4388o.htm |
| 2023-02-01 | 6-K | 2023-02-01 | BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA | a4987o.htm |
| 2023-02-01 | 6-K | 2023-02-01 | FINAL RESULTS | a4922o.htm |
| 2023-01-18 | 6-K | 2023-01-18 | DIRECTOR/PDMR SHAREHOLDING | a1687n.htm |
| 2023-01-17 | 6-K | 2023-01-17 | DIRECTOR/PDMR SHAREHOLDING | a0217n.htm |
| 2023-01-17 | 6-K | 2023-01-17 | DIRECTOR/PDMR SHAREHOLDING | a8770m.htm |
| 2023-01-13 | 6-K | 2023-01-13 | DIRECTOR/PDMR SHAREHOLDING | a7261m.htm |
| 2023-01-12 | 6-K | 2023-01-12 | DIRECTOR/PDMR SHAREHOLDING | a5834m.htm |
| 2023-01-03 | 6-K | 2023-01-03 | TOTAL VOTING RIGHTS | a5542l.htm |